{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:56:57Z","timestamp":1782568617391,"version":"3.54.5"},"reference-count":102,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHMRC Early Career Fellowship","award":["GNT1147154"],"award-info":[{"award-number":["GNT1147154"]}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["GNT1176437"],"award-info":[{"award-number":["GNT1176437"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Several GnRH antagonist protocols are currently used during COS in the context of ART treatments; however, questions remain regarding whether these protocols are comparable in terms of efficacy and safety.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE AND RATIONALE<\/jats:title><jats:p>A systematic review followed by a pairwise and network meta-analyses were performed. The systematic review and pairwise meta-analysis of direct comparative data according to the PRISMA guidelines evaluated the effectiveness of different GnRH antagonist protocols (fixed Day 5\/6 versus flexible, ganirelix versus cetrorelix, with or without hormonal pretreatment) on the probability of live birth and ongoing pregnancy after COS during ART treatment. A frequentist network meta-analysis combining direct and indirect comparisons (using the long GnRH agonist protocol as the comparator) was also performed to enhance the precision of the estimates.<\/jats:p><\/jats:sec><jats:sec><jats:title>SEARCH METHODS<\/jats:title><jats:p>The systematic literature search was performed using Embase (Ovid), MEDLINE (Ovid), Cochrane Central Register of Trials (CENTRAL), SCOPUS and Web of Science (WOS), from inception until 23 November 2021. The search terms comprised three different MeSH terms that should be present in the identified studies: GnRH antagonist; assisted reproduction treatment; randomized controlled trial (RCT). Only studies published in English were included.<\/jats:p><\/jats:sec><jats:sec><jats:title>OUTCOMES<\/jats:title><jats:p>The search strategy resulted in 6738 individual publications, of which 102 were included in the systematic review (corresponding to 75 unique studies) and 73 were included in the meta-analysis. Most studies were of low quality. One study compared a flexible protocol with a fixed Day 5 protocol and the remaining RCTs with a fixed Day 6 protocol. There was a lack of data regarding live birth when comparing the flexible and fixed GnRH antagonist protocols or cetrorelix and ganirelix. No significant difference in live birth rate was observed between the different pretreatment regimens versus no pretreatment or between the different pretreatment protocols. A flexible GnRH antagonist protocol resulted in a significantly lower OPR compared with a fixed Day 5\/6 protocol (relative risk (RR) 0.76, 95% CI 0.62 to 0.94, I2\u2009=\u20090%; 6 RCTs; n\u2009=\u2009907 participants; low certainty evidence). There were insufficient data for a comparison of cetrorelix and ganirelix for OPR. OCP pretreatment was associated with a lower OPR compared with no pretreatment intervention (RR 0.79, 95% CI 0.69 to 0.92; I2\u2009=\u20090%; 5 RCTs, n\u2009=\u20091318 participants; low certainty evidence). Furthermore, in the network meta-analysis, a fixed protocol with OCP resulted in a significantly lower OPR than a fixed protocol with no pretreatment (RR 0.84, 95% CI 0.71 to 0.99; moderate quality evidence). The surface under the cumulative ranking (SUCRA) scores suggested that the fixed protocol with no pretreatment is the antagonist protocol most likely (84%) to result in the highest OPR. There was insufficient evidence of a difference between fixed\/flexible or OCP pretreatment\/no pretreatment interventions regarding other outcomes, such as ovarian hyperstimulation syndrome and miscarriage rates.<\/jats:p><\/jats:sec><jats:sec><jats:title>WIDER IMPLICATIONS<\/jats:title><jats:p>Available evidence, mostly of low quality and certainty, suggests that different antagonist protocols should not be considered as equivalent for clinical decision-making. More trials are required to assess the comparative effectiveness of ganirelix versus cetrorelix, the effect of different pretreatment interventions (e.g. progestins or oestradiol) or the effect of different criteria for initiation of the antagonist in the flexible protocol. Furthermore, more studies are required examining the optimal GnRH antagonist protocol in women with high or low response to ovarian stimulation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/humupd\/dmac040","type":"journal-article","created":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T13:16:43Z","timestamp":1672751803000},"page":"307-326","source":"Crossref","is-referenced-by-count":45,"title":["What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis"],"prefix":"10.1093","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9591-7222","authenticated-orcid":false,"given":"C A","family":"Venetis","sequence":"first","affiliation":[{"name":"University of New South Wales, Faculty of Medicine & Health, Centre for Big Data Research in Health & Discipline of Obstetrics and Gynaecology , Sydney, Australia"},{"name":"IVFAustralia , Alexandria, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Storr","sequence":"additional","affiliation":[{"name":"Flinders Fertility , Adelaide, SA, Australia"},{"name":"College of Medicine and Public Health, Flinders University , Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-2302","authenticated-orcid":false,"given":"S J","family":"Chua","sequence":"additional","affiliation":[{"name":"Austin Health , Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8337-550X","authenticated-orcid":false,"given":"B W","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash University , Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Longobardi","sequence":"additional","affiliation":[{"name":"Global Clinical Development, Merck Serono S.p.A , Rome, Italy, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Yin","sequence":"additional","affiliation":[{"name":"EMD Serono Inc., R&D Global Biostatistics, Epidemiology & Medical Writing , Billerica, MA, USA, an affiliate of Merck KGaA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-8257","authenticated-orcid":false,"given":"T","family":"D\u2019Hooghe","sequence":"additional","affiliation":[{"name":"Merck Healthcare KGaA , Darmstadt, Germany"},{"name":"Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine , KU Leuven, Leuven, Belgium"},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School , New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"2023051110291359000_dmac040-B1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/humrep\/15.3.526","article-title":"Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group","volume":"15","author":"Albano","year":"2000","journal-title":"Hum Reprod"},{"issue":"1","key":"2023051110291359000_dmac040-B178","first-page":"i47","article-title":"Effectiveness of flexible GnRH antagonist protocol versus minidose long GnRH agonist protocol in poor-responder patients undergoing IVF","volume":"26","author":"Al-Karaki","year":"2011","journal-title":"Human Reproduction"},{"key":"2023051110291359000_dmac040-B2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1472-6483(10)61661-6","article-title":"Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol","volume":"10","author":"Al-Inany","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B3","first-page":"CD001750","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2023051110291359000_dmac040-B4","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/humrep\/der318","article-title":"Predictive factors of ovarian response and clinical outcome after IVF\/ICSI following a rFSH\/GnRH antagonist protocol with or without oral contraceptive pre-treatment","volume":"26","author":"Andersen","year":"2011","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B161","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/humrep\/del484","article-title":"Milder ovarian stimulation for in-vitro fertilization reduces aneuploidy in the human preimplantation embryo: a randomized controlled trial","volume":"22","author":"Baart","year":"2007","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B151","first-page":"49","article-title":"Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis","volume":"10","author":"Badrawi","year":"2005","journal-title":"Middle East Fertility Society Journal"},{"key":"2023051110291359000_dmac040-B173","first-page":"84","article-title":"Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study","volume":"50","author":"Bah\u00e7eci","year":"2005","journal-title":"J Reprod Med"},{"key":"2023051110291359000_dmac040-B157","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2004.06.076","article-title":"A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist\/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist\/rFSH in women pretreated with oral contraceptives before in vitro fertilization","volume":"83","author":"Barmat","year":"2005","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.fertnstert.2009.01.003","article-title":"Return to fertility following discontinuation of oral contraceptives","volume":"91","author":"Barnhart","year":"2009","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B6","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/S0015-0282(02)03784-6","article-title":"An embryonic perspective of a comparative randomized study of Lupron\/Follistim versus Follistim\/Antagon in IVF","volume":"78","author":"Batzofin","year":"2002","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.rbmo.2011.11.012","article-title":"Oestradiol valerate pretreatment in GnRH-antagonist cycles: a randomized controlled trial","volume":"24","author":"Blockeel","year":"2012","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/humrep\/15.7.1490","article-title":"Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group","volume":"15","author":"Borm","year":"2000","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B9","doi-asserted-by":"crossref","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","article-title":"ESHRE guideline: ovarian stimulation for IVF\/ICSI","volume":"2020","author":"Bosch","year":"2020","journal-title":"Hum Reprod Open"},{"key":"2023051110291359000_dmac040-B10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/humrep\/del340","article-title":"Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol","volume":"22","author":"C\u00e9drin-Durnerin","year":"2007","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.fertnstert.2012.02.028","article-title":"Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial","volume":"97","author":"C\u00e9drin-Durnerin","year":"2012","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B162","first-page":"257","article-title":"Effect of antagonists vs agonists on in vitro fertilization outcome","volume":"31","author":"Check","year":"2004","journal-title":"Clin Exp Obstet Gynecol"},{"key":"2023051110291359000_dmac040-B160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/humrep\/deh668","article-title":"GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial","volume":"20","author":"Cheung","year":"2005","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B176","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1477-7827-10-33","article-title":"GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology","volume":"10","author":"Cota","year":"2012","journal-title":"Reprod Biol Endocrinol"},{"key":"2023051110291359000_dmac040-B12","year":"2019"},{"key":"2023051110291359000_dmac040-B13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.29252\/ijrm.16.3.175","article-title":"Endogenous luteinizing hormone concentration and IVF outcome during ovarian stimulation in fixed versus flexible GnRH antagonist protocols: an RCT","volume":"16","author":"Depalo","year":"2018","journal-title":"Int J Reprod Biomed"},{"key":"2023051110291359000_dmac040-B14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2023051110291359000_dmac040-B15","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1093\/humrep\/13.9.2392","article-title":"Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers","volume":"13","author":"Duijkers","year":"1998","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B16","doi-asserted-by":"crossref","first-page":"E324","DOI":"10.1016\/j.fertnstert.2015.07.1012","article-title":"The predictive value of early follicular progesteron on preovulatuary progesteron rise in IVF cycles with GNRH antagonist protocol","volume":"104","author":"Erdem","year":"2015","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.fertnstert.2003.07.027","article-title":"Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients","volume":"81","author":"Escudero","year":"2004","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/humrep\/16.4.644","article-title":"Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation","volume":"16","author":"European and Middle East Orgalutran Study Group","year":"2001","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B19","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/humrep\/deg516","article-title":"Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists","volume":"18","author":"Fanchin","year":"2003","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.rbmo.2017.03.024","article-title":"Management of ovarian stimulation for IVF: narrative review of evidence provided for World Health Organization guidance","volume":"35","author":"Farquhar","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/01443615.2021.1916806","article-title":"Use of steroid pre-treatments in IVF-ICSI cycles with GnRH antagonist protocol and their impact on gestational outcomes","volume":"42","author":"Fernandez-Prada","year":"2022","journal-title":"J Obstet Gynaecol"},{"key":"2023051110291359000_dmac040-B177","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejogrb.2005.08.017","article-title":"Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist\/FSH ovarian stimulation cycles","volume":"124","author":"Ferrari","year":"2006","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2023051110291359000_dmac040-B22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0015-0282(00)01638-1","article-title":"Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation","volume":"75","author":"Fluker","year":"2001","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B163","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.fertnstert.2006.05.078","article-title":"Effects of gonadotropin-releasing hormone agonist\/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist\/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization","volume":"87","author":"Fornaro","year":"2007","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B179","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1472-6483(10)60976-5","article-title":"Luteal phase characteristics following GnRH antagonist or agonist treatment \u2013 a comparative study","volume":"12","author":"Friedler","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B159","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.fertnstert.2011.06.022","article-title":"Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial","volume":"96","author":"Garcia-Velasco","year":"2011","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B23","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.fertnstert.2010.04.025","article-title":"Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis","volume":"94","author":"Griesinger","year":"2010","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2023051110291359000_dmac040-B25","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"2023051110291359000_dmac040-B26","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"2023051110291359000_dmac040-B27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1477-7827-11-96","article-title":"Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial","volume":"11","author":"Hauzman","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"2023051110291359000_dmac040-B174","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00404-012-2348-9","article-title":"IVF\/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial","volume":"286","author":"Haydardedeoglu","year":"2012","journal-title":"Arch Gynecol Obstet"},{"key":"2023051110291359000_dmac040-B28","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1093\/humrep\/15.6.1211","article-title":"Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists","volume":"15","author":"Hernandez","year":"2000","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.rbmo.2016.11.010","article-title":"\u2018Model\u2019 versus \u2018everyday\u2019 patients: can randomized controlled trial data really be applied to the clinic?","volume":"34","author":"Hershkop","year":"2017","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B30","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2023051110291359000_dmac040-B31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"2023051110291359000_dmac040-B32","first-page":"141","article-title":"Fixed versus flexible gonadotropin releasing hormone antagonist protocol in controlled ovarian stimulation for invitro fertilization in women with polycystic ovary syndrome","volume":"9","author":"Hossein Rashidi","year":"2015","journal-title":"J Family Reprod Health"},{"key":"2023051110291359000_dmac040-B184","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1447-0756.2010.01247.x","article-title":"Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients","volume":"36","author":"Hosseini","year":"2010","journal-title":"J Obstet Gynaecol Res"},{"key":"2023051110291359000_dmac040-B34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1472-6483(10)60621-9","article-title":"Effect of an oral contraceptive pill on follicular development in IVF\/ICSI patients receiving a GnRH antagonist: a randomized study","volume":"13","author":"Huirne","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B155","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/humrep\/del030","article-title":"Cetrorelix in an OC pretreated stimulation cycle compared to buserelin in IVF\/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study","volume":"21","author":"Huirne","year":"2006","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B33","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0140-6736(01)06797-6","article-title":"Gonadotropin-releasing-hormone-receptor antagonists","volume":"358","author":"Huirne","year":"2001","journal-title":"Lancet"},{"key":"2023051110291359000_dmac040-B35","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2023051110291359000_dmac040-B36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2023051110291359000_dmac040-B152","first-page":"i115","article-title":"Randomized comparison of GnRH antagonist and agonist regimen in 35 years of age or older undergoing ICSI","volume":"21","author":"Karabacak","year":"2006","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B37","first-page":"234","article-title":"Comparison of NuvaRing and Desogen in IVF cycles with ganirelix acetate","volume":"57","author":"Karande","year":"2007","journal-title":"J Obstet Gynecol India"},{"key":"2023051110291359000_dmac040-B38","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1016\/j.fertnstert.2007.07.624","article-title":"A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome","volume":"88","author":"Kars","year":"2007","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5653\/cerm.2011.38.4.228","article-title":"GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF\/ICSI","volume":"38","author":"Kim","year":"2011","journal-title":"Clin Exp Reprod Med"},{"key":"2023051110291359000_dmac040-B181","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejogrb.2014.12.021","article-title":"GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial","volume":"185","author":"Klement","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2023051110291359000_dmac040-B40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/humrep\/dei348","article-title":"Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial","volume":"21","author":"Kolibianakis","year":"2006","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B41","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.fertnstert.2010.05.052","article-title":"Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial","volume":"95","author":"Kolibianakis","year":"2011","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B154","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10815-008-9249-7","article-title":"Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study","volume":"25","author":"Kurzawa","year":"2008","journal-title":"J Assist Reprod Genet"},{"issue":"3","key":"2023051110291359000_dmac040-B175","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1093\/humrep\/dep436","article-title":"Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT)","volume":"25","author":"Lainas","year":"2010","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B180","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.fertnstert.2004.04.051","article-title":"A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol","volume":"82","author":"Loutradis","year":"2004","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B42","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/humrep\/17.11.2842","article-title":"Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study","volume":"17","author":"Ludwig","year":"2002","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12884-021-03833-2","article-title":"Fixed versus flexible antagonist protocol in women with predicted high ovarian response except PCOS: a randomized controlled trial","volume":"21","author":"Luo","year":"2021","journal-title":"BMC Pregnancy Childbirth"},{"key":"2023051110291359000_dmac040-B44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.fertnstert.2017.12.021","article-title":"Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist","volume":"109","author":"Lyttle Schumacher","year":"2018","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B164","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1472-6483(10)60957-1","article-title":"GnRH antagonist in IVF poor-responder patients: results of a randomized trial","volume":"11","author":"Marci","year":"2005","journal-title":"Reprod Biomed Online"},{"key":"2023051110291359000_dmac040-B45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13643-017-0473-z","article-title":"Approaches to interpreting and choosing the best treatments in network meta-analyses","volume":"6","author":"Mbuagbaw","year":"2017","journal-title":"Syst Rev"},{"key":"2023051110291359000_dmac040-B46","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/humrep\/deh334","article-title":"The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF\/ICSI","volume":"19","author":"Mochtar","year":"2004","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B47","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2023051110291359000_dmac040-B186","first-page":"148","article-title":"ART Outcomes in GnRH Antagonist Protocol (Flexible) and Long GnRH Agonist Protocol during Early Follicular Phase in Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial","volume":"16","author":"Mokhtar","year":"2015","journal-title":"J Reprod Infertil"},{"key":"2023051110291359000_dmac040-B185","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12325-008-0028-8","article-title":"Comparison of GnRH Agonists and Antagonists in Normoresponder IVF\/ICSI in Turkish Female Patients","volume":"25","author":"Moraloglu","year":"2008","journal-title":"Adv Ther"},{"key":"2023051110291359000_dmac040-B48","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2023051110291359000_dmac040-B49","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0015-0282(99)00524-5","article-title":"Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin)","volume":"73","author":"Olivennes","year":"2000","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jcma.2017.01.011","article-title":"Are there any differences between antagonist administration on days &lt;6 and &gt;\/=6 of controlled ovarian hyperstimulation on assisted reproductive technique outcomes?","volume":"81","author":"Ozturk Inal","year":"2018","journal-title":"J Chin Med Assoc"},{"key":"2023051110291359000_dmac040-B165","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.fertnstert.2006.12.046","article-title":"GnRH agonist and antagonist protocols for stage I\u2013II endometriosis and endometrioma in in vitro fertilization\/intracytoplasmic sperm injection cycles","volume":"88","author":"Pabuccu","year":"2007","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B188","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejogrb.2012.09.008","article-title":"GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial","volume":"166","author":"Prapas","year":"2013","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2023051110291359000_dmac040-B166","first-page":"1063","article-title":"Investigation of pregnancy outcome and ovarian hyper stimulation syndrome prevention in agonist and antagonist gonadotropin-releasing hormone protocol","volume":"17","author":"Rabati","year":"2012","journal-title":"J Res Med Sci"},{"key":"2023051110291359000_dmac040-B51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/humrep\/dei302","article-title":"A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients","volume":"21","author":"Rombauts","year":"2006","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2023051110291359000_dmac040-B167","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.fertnstert.2008.02.165","article-title":"Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40","volume":"91","author":"Sbracia","year":"2009","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B182","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.fertnstert.2006.02.110","article-title":"Ovarian stimulation with daily late follicular phase administration of low-dose human chorionic gonadotropin for in vitro fertilization: a prospective, randomized trial","volume":"86","author":"Serafini","year":"2006","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B53","doi-asserted-by":"crossref","first-page":"535","DOI":"10.29252\/ijrm.16.8.535","article-title":"Comparison of pre-treatment with OCPs or estradiol valerate vs. no pre-treatment prior to GnRH antagonist used for IVF cycles: an RCT","volume":"16","author":"Shahrokh Tehrani Nejad","year":"2018","journal-title":"Int J Reprod Biomed"},{"key":"2023051110291359000_dmac040-B189","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5653\/cerm.2018.45.3.135","article-title":"Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: A preliminary randomized trial","volume":"45","author":"Shin","year":"2018","journal-title":"Clin Exp Reprod Med"},{"key":"2023051110291359000_dmac040-B54","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"2023051110291359000_dmac040-B169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.fertnstert.2013.09.035","article-title":"Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial","volume":"101","author":"Sunkara","year":"2014","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B55","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2012.11.020","article-title":"The effect of delayed initiation of gonadotropin-releasing hormone antagonist in a flexible protocol on in vitro fertilization outcome","volume":"99","author":"Tannus","year":"2013","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B168","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00404-008-0620-9","article-title":"Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial","volume":"278","author":"Tazeg\u00fcl","year":"2008","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"2023051110291359000_dmac040-B170","first-page":"165","article-title":"Multi-dose GnRH Antagonist versus Long GnRH Agonist Protocol in Poor Responders: A Randomized Controlled Trial","volume":"2","author":"Tehraninejad","year":"- 2009","journal-title":"International Journal of Fertility and Sterility"},{"key":"2023051110291359000_dmac040-B171","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00404-010-1429-x","article-title":"Comparison of GnRH antagonist with long GnRH agonist protocol after OCP pretreatment in PCOs patients","volume":"282","author":"Tehraninejad","year":"2010","journal-title":"Arch Gynecol Obstet"},{"issue":"3","key":"2023051110291359000_dmac040-B172","first-page":"171","article-title":"GnRH antagonist versus agonist in normoresponders undergoing ICSI: a randomized clinical trial in","volume":"9","author":"Tehraninejad","year":"2011","journal-title":"Iran Iranian Journal of Reproductive Medicine"},{"key":"2023051110291359000_dmac040-B187","doi-asserted-by":"crossref","first-page":"265","DOI":"10.17772\/gp\/62205","article-title":"Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: comparison of clinical outcome and embryo quality","volume":"87","author":"Trenki\u0107","year":"2016","journal-title":"Ginekol Pol"},{"key":"2023051110291359000_dmac040-B56","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/17425250903279969","article-title":"GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology","volume":"5","author":"Tur-Kaspa","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2023051110291359000_dmac040-B57","doi-asserted-by":"crossref","first-page":"622","DOI":"10.2174\/1389201018666170808130526","article-title":"Gonadotropin releasing hormone agonists or antagonists for preimplantation genetic diagnosis (PGD)? A prospective randomised trial","volume":"18","author":"Verpoest","year":"2017","journal-title":"Curr Pharm Biotechnol"},{"key":"2023051110291359000_dmac040-B58","doi-asserted-by":"crossref","first-page":"S252","DOI":"10.1016\/j.fertnstert.2011.07.968","article-title":"Oral contraceptive (OcP) pretreatment achieves better pregnancy rates in in vitro fertilization (IVF) antagonists GnRH flexible protocols: a prospective randomized study","volume":"96","author":"Vilela","year":"2011","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I(2) can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2023051110291359000_dmac040-B183","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejogrb.2004.11.005","article-title":"A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy","volume":"120","author":"Xavier","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2023051110291359000_dmac040-B60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/humrep\/dew325","article-title":"Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome","volume":"32","author":"Wei","year":"2017","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B61","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"2023051110291359000_dmac040-B62","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"The Stata Journal"},{"key":"2023051110291359000_dmac040-B63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.fertnstert.2005.03.016","article-title":"Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies","volume":"84","author":"Wilcox","year":"2005","journal-title":"Fertil Steril"},{"key":"2023051110291359000_dmac040-B153","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/humrep\/deaa086","article-title":"The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study","volume":"35","author":"Xu","year":"2020","journal-title":"Hum Reprod"},{"key":"2023051110291359000_dmac040-B158","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10815-009-9300-3","article-title":"IVF\/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study","volume":"26","author":"Ye","year":"2009","journal-title":"J Assist Reprod Genet"},{"key":"2023051110291359000_dmac040-B64","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.fertnstert.2009.09.009","article-title":"International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009","volume":"92","author":"Zegers-Hochschild","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Human Reproduction Update"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/29\/3\/307\/50276459\/dmac040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humupd\/article-pdf\/29\/3\/307\/50276459\/dmac040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:28:39Z","timestamp":1701444519000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humupd\/article\/29\/3\/307\/6967440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":102,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,3]]},"published-print":{"date-parts":[[2023,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/humupd\/dmac040","relation":{},"ISSN":["1355-4786","1460-2369"],"issn-type":[{"value":"1355-4786","type":"print"},{"value":"1460-2369","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2023,1,3]]}}}